Mary Grecco

DocwireNews

The standard of care for patients with inoperable stage III NSCLC is chemoradiotherapy (CRT) and adjuvant durvalumab (IO) for 12 months. Pneumonitis is the most common toxicity that leads to IO discontinuation, but failure to distinguish between radiation-induced changes, IO pneumonitis, and infection can lead to unnecessary IO discontinuation. Results of a study that investigated the use of a structured multidisciplinary review of CT scans, radiation dose distributions, and clinical symptoms for the diagnosis of IO pneumonitis were presented at the ESMO Congress 2023.The researchers conducted a retrospective study at an academic medical center for patients with stage III NSCLC treated with CRT and adjuvant IO between 2018 and 2021, and expert clinicians and radiologists reviewed baseline and follow-up CT scans, radiological features consistent with pneumonitis, and radiation dose distributions. A final consensus diagnosis incorporating views of the expert clinicians and the radiologist was made, and a diagnosis of IO pneumonitis was made only when both the radiologist and pulmonologists were in agreement.Results showed that among 45 patients, 14 (31.1%) had a pneumonitis scored in patient records, and IO was discontinued in 11 of 45 (24.4%). Review by the radiologist led to a diagnosis of IO pneumonitis in just six patients (13.3%) and by the expert clinicians in only four (8.9%). In addition, suspicion of IO pneumonitis was rejected in three separate patients (6.7%) after the clinicians reviewed the patient&rsquo;s radiation fields.The researchers concluded that in patients treated using the PACIFIC regimen of IO, a multidisciplinary assessment of CT scans, radiation doses, and patient symptoms resulted in fewer diagnoses of IO pneumonitis (8.9%). &ldquo;In contrast, routine clinical assessment by treating pulmonary oncologists led to discontinuation of IO in 24.4% of patients. This [finding] highlights the need for multidisciplinary review in order to avoid inappropriate cessation of adjuvant IO.&rdquo;Source: Smesseim I, Mets O, Daniels HMA, et al. A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer. Abstract of a poster presented at the ESMO Congress 2023; October 20-24, 2023; Madrid, Spain.

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

Immune-Related Pneumonitis in Patients Undergoing Adjuvant Durvalumab for NSCLC

ESMO 2023: Focus on Lung Cancer

A study investigated the use of a structured multidisciplinary review for the diagnosis of IO pneumonitis in NSCLC.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe